JP Morgan: HSBC HOLDINGS (00005) sells its Australian retail business to advance its streamlining strategy, with a minimal financial impact.
Morgan Stanley believes that the sale allows HSBC to focus on businesses with stronger competitive advantages and growth opportunities. They reiterated their "Overweight" rating with a target price of 200 HKD.
J.P. Morgan released a research report stating that HSBC HOLDINGS (00005) announced the sale of its AU$36 billion (approximately US$24.9 billion) residential and personal loan portfolio in Australia to funds managed by Blackstone (BX.US), and will gradually wind down the remainder of its retail operations in Australia over the next 18 months. The transaction was anticipated and is seen as slightly positive, as it signifies further advancement of the management's streamlining strategy. The financial impact is minor, with an expected effect on the Common Equity Tier 1 (CET1) capital ratio of only about 3 basis points by 2027, and an estimated cumulative loss of about US$600 million from 2026 to 2028, which is only about 0.5% of the market's expected pre-tax profit for that period. HSBC will retain and continue to invest in its corporate and institutional banking, private banking, and asset management businesses in Australia. J.P. Morgan believes that this sale allows HSBC to focus on businesses with stronger competitive advantages and growth opportunities, reiterating an Overweight rating with a target price of HK$200.
HSBC expects the transaction to be completed in the first half of 2027, pending regulatory and competition approvals. The group anticipates total costs and write-offs of approximately US$300 million from 2026 to 2027, which includes around US$200 million in costs and write-offs related to this portfolio and less than US$100 million in losses from the portfolio sale. The group expects that by 2028, it will reverse approximately US$300 million of foreign exchange reserve losses, which will not have an additional impact on CET1. All related impacts will be classified as significant non-recurring items and excluded from the dividend payout ratio target benchmark.
Related Articles

HK Stock Market Move | LEADS BIOLABS-B (09887) rose over 3% as the phase II clinical research of WeiliXin for the first-line treatment of hepatocellular carcinoma successfully entered the expansion phase.

HK Stock Market Move | GENSCRIPT BIO (01548) rose over 5% again. Performance results will be announced in mid-March. Sales of CARVYKTI in the first half of the year increased significantly year-on-year.

HK Stock Market Move | APEX ACE HLDG (06036) surged over 18% during trading, expecting the net profit attributable to shareholders for the first half of the year to grow to HKD 130 million to HKD 140 million compared to the same period last year.
HK Stock Market Move | LEADS BIOLABS-B (09887) rose over 3% as the phase II clinical research of WeiliXin for the first-line treatment of hepatocellular carcinoma successfully entered the expansion phase.

HK Stock Market Move | GENSCRIPT BIO (01548) rose over 5% again. Performance results will be announced in mid-March. Sales of CARVYKTI in the first half of the year increased significantly year-on-year.

HK Stock Market Move | APEX ACE HLDG (06036) surged over 18% during trading, expecting the net profit attributable to shareholders for the first half of the year to grow to HKD 130 million to HKD 140 million compared to the same period last year.

RECOMMEND





